Valion Bio, Inc.
VBIO
Rank in Stocks
#32801
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead... Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.
Share Price
$0.54165
Last synced: 2026-11-09
Market Cap
$1.17M
Change (1 day)
6.23%
Change (1 year)
-76.14%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Valion Bio, Inc. (VBIO)
Category
Healthcare
Operating Margin for Valion Bio, Inc. (VBIO)
Operating Margin as of November 2026 TTM: 10,587.18%
According to Valion Bio, Inc.'s latest financial reports, its current operating margin (TTM) is 10,587.18%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Valion Bio, Inc. from 2009 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 10,587.18% | 0.00% |
| 2025 | 0.00% | 0.00% |
| 2024 | 0.00% | -100.00% |
| 2023 | 9.07% | -139.83% |
| 2022 | -22.77% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | -100.00% |
| 2018 | -4,292.90% | 102.01% |
| 2017 | -2,125.05% | 92.49% |
| 2016 | -1,104.00% | -28.72% |
| 2015 | -1,548.83% | 0.00% |
| 2014 | 0.00% | 0.00% |
| 2013 | 0.00% | 0.00% |
| 2012 | 0.00% | 0.00% |
| 2011 | 0.00% | 0.00% |
| 2010 | 0.00% | 0.00% |
| 2009 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.00% |
US
|
|
| -149.01% | -100.01% |
US
|
|
| 25.57% | -100.00% |
AU
|
|
| 31.23% | -100.00% |
BE
|
|
| 29.35% | -100.00% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Valion Bio, Inc.'s operating margin
What is Valion Bio, Inc.'s operating margin?
Valion Bio, Inc.'s operating margin is 10,587.18%, as of Nov 2026.
What was Valion Bio, Inc.'s operating margin in 2025?
In 2025, Valion Bio, Inc.'s operating margin was 0.00%, compared with 0.00% in 2024.
How has Valion Bio, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Valion Bio, Inc.'s operating margin was highest in 2023 (9.07%) and lowest in 2022 (-22.77%).
How does Valion Bio, Inc.'s operating margin compare with similar companies?
Valion Bio, Inc.'s operating margin (10,587.18%) is higher than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.